Atidem

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atidem

Property Description
Active Ingredient Piroxicam (INN)
Form Capsule, tablet, topical gel, parenteral solution
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Relief of pain, inflammation, and fever
Origin Synthetic compound

What is the Active Ingredient in Atidem and Its Pharmacological Class?

Atidem is a trademark name for a medicinal product containing the active ingredient Piroxicam, a substance chemically identified as an enolic acid derivative. Piroxicam is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and belongs specifically to the oxicam class of these agents. This compound is synthetic in origin and utilized as a single-ingredient medicine, concentrating its therapeutic effect exclusively through the properties of Piroxicam. The general anti-inflammatory capacity of Piroxicam is clinically recognized for managing conditions characterized by chronic discomfort and swelling.

What Forms is Piroxicam Available in and What is its General Purpose?

Piroxicam is available in several dosage forms, most commonly as oral capsules or tablets, but also as a topical gel for application to the skin, and sometimes in parenteral formulations for injection. This variety in form is one of the drug's differentiating features, allowing for either systemic or localized treatment. The general purpose of this medication is to provide symptomatic relief by reducing inflammation, lessening associated pain, and helping to control fever through its effect on inflammatory mediators.

Unique Properties of Piroxicam

The classification of Piroxicam as an oxicam NSAID is based on its specific chemical structure. This structural characteristic contributes to a notable pharmacological feature: a long half-life, which is approximately 50 hours. This extended duration of activity means that Piroxicam's effects are sustained over a long duration, allowing for a simplified dosing schedule compared to shorter-acting anti-inflammatory agents. This property makes Piroxicam particularly suitable for managing persistent inflammatory symptoms in adult patients.

Regulatory References

  1. Piroxicam - LiverTox - NIH
  2. PIROXICAM capsule - DailyMed

What side effects are possible with Atidem?

Possible Side Effects and Safety Information

The safety profile of Piroxicam, the active ingredient in Atidem, is formally categorized by regulatory authorities to communicate documented risks and potential adverse reactions.

Adverse Reaction Classifications

Side effects are grouped by frequency and the body system affected. Common reactions (occurring in 1% to 10% of patients) typically involve the Gastrointestinal Disorders (such as nausea, dyspepsia, and abdominal pain) and the Nervous System Disorders (including headache and dizziness). Events classified as Very Rare include severe and potentially life-threatening skin reactions.

Serious Adverse Reactions and Risk Patterns

The official labeling documents several Serious Adverse Reactions. These include the risk of Gastrointestinal Hemorrhage, Ulceration, or Perforation, and the risk of serious Cardiovascular Thrombotic Events such as Myocardial Infarction and Stroke. Regulatory documents specify that the risk of these serious GI and CV events increases with the duration of use and is considered dose-dependent.

Population-Specific Safety Notes

Specific safety considerations are noted for certain groups. Older Adults are classified as being at a higher risk for developing serious gastrointestinal complications and renal toxicity. Furthermore, use is contraindicated from the start of the sixth month of pregnancy due to documented fetal risks. The drug is also not recommended for use in patients with severe cardiac, hepatic, or renal impairment, and concomitant use with other systemic non-aspirin nonsteroidal anti-inflammatory drugs is generally avoided.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Piroxicam is officially documented to present with gastrointestinal manifestations such as nausea, vomiting, abdominal pain, and potentially signs of peptic ulceration or gastrointestinal bleeding. Central nervous system effects are also recorded in regulatory labeling, including drowsiness, confusion, severe headache, hyperreflexia, and tinnitus.

Regulators define severe or life-threatening outcomes that can occur, including convulsions (seizures), decreased level of consciousness leading to coma, low blood pressure (shock), and the potential for acute kidney injury or chronic liver injury. Urgent medical attention is mandated due to the risk of these systemic complications.

Immediate medical attention must be sought upon suspected overdosage. Government labeling strictly instructs individuals to contact emergency services or a poison control center immediately and not to delay calling for help.

No specific antidote is known for Piroxicam. Treatment is officially defined as entirely symptomatic and supportive. Management procedures documented in regulatory sources include monitoring of vital signs, hospital observation, and consideration of interventions such as gastric lavage or administration of activated charcoal.

Therapeutic Uses of Atidem

What Atidem Treats: Main Uses and Benefits

Piroxicam (Atidem) is considered relevant for easing symptoms related to inflammatory or irritative states, primarily within the rheumatologic and musculoskeletal domains. This medication is used to provide symptomatic relief from pronounced pain, tenderness, swelling, and stiffness caused by specific conditions. It is commonly used to help manage symptoms related to chronic inflammatory processes, particularly Osteoarthritis and Rheumatoid Arthritis.

It is also relevant in conditions involving episodic or fluctuating manifestations, such as a severe Acute Gouty Arthritis flare-up, localized tissue swelling from tendinitis or bursitis, and the painful episodes of Primary Dysmenorrhea. The supportive relief helps patients cope more steadily with symptom fluctuations, contributing to improved day-to-day comfort and assisting with maintaining functional stability. This general symptomatic benefit is considered relevant in clinical settings.

“Applied in scenarios where additional management of discomfort is required, this support offers symptomatic therapeutic benefit during difficult episodes.”


Symptomatic Summary: Relief for Joint Inflammation

The medication is applied across domains where additional symptomatic support is needed to address symptom clusters that create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Atidem

The eligibility profile for using Atidem is determined by official regulatory bodies, which establish the populations for whom the medication is authorized and those for whom its use is strictly restricted or prohibited. This information is drawn from authoritative government documentation (such as FDA Prescribing Information or EMA Summary of Product Characteristics).

Field Eligibility Status (as per Official Labeling)
Populations for whom use is allowed Established for the indicated patient population meeting all inclusion criteria.
Populations for whom use is contraindicated Patients with a known hypersensitivity to the active substance or any component of the formulation.
Age-related eligibility rules Use may be restricted or not established in specific age groups, such as pediatric patients (children and adolescents). The authorized minimum age for use is defined by the label.
Pregnancy and lactation eligibility Status is defined by the label; use may be not recommended or contraindicated during pregnancy or breastfeeding due to potential fetal/infant risk.
Condition-specific eligibility rules Restrictions apply to patients with specific comorbidities, such as severe hepatic impairment or renal impairment, where altered drug metabolism or increased risk is documented.

Connection to the overall eligibility profile

The official eligibility profile is structured around two key areas: mandatory exclusions and conditional use. Regulatory documents explicitly prohibit use in contraindicated populations, while defining conditional use through specific limitations related to age, physiological status (pregnancy/lactation), and the presence of organ impairment. This framework ensures that the medicine is reserved strictly for those patients whose profile aligns with the authorized safety and efficacy data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the product's interaction structure around pharmacokinetic and pharmacodynamic profiles.

Interaction Type Interacting Substances/Categories Regulatory Description of Outcome
Contraindicated Combinations Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Anticoagulants Increased risk of serious bleeding and gastrointestinal adverse events. Co-administration is formally prohibited in many regions.
Pharmacokinetic Profile CYP2C9 Inhibitors (e.g., Fluconazole) Co-administration may increase Piroxicam's plasma concentration due to reduced metabolic clearance via the CYP2C9 enzyme.
Pharmacodynamic Reinforcement Antiplatelet Agents, SSRIs, SNRIs Additive antiplatelet effects documented to increase the overall risk of serious bleeding.
Exposure Modification Lithium, Methotrexate Inhibits the clearance of these medicines, leading to an increase in their plasma concentrations and potential toxicity.
Efficacy Reduction ACE Inhibitors, ARBs, Diuretics May diminish the antihypertensive or natriuretic effects of these agents.

Co-administration with analgesic doses of aspirin is generally not recommended due to a heightened risk of serious gastrointestinal complications. The consumption of alcohol is documented to increase the risk of gastrointestinal adverse events, including bleeding. Population-specific cautions exist, noting that co-administration with ACE Inhibitors or ARBs may increase the risk of renal function deterioration in elderly patients and those with pre-existing renal impairment.

Mechanism of Action

The primary action of Atidem (Piroxicam) is to act as a non-selective reversible inhibitor of the Cyclooxygenase ( COX) enzymes, specifically COX-1 and COX-2. This molecular action directly targets the Arachidonic Acid Cascade, blocking the conversion of arachidonic acid into pro-inflammatory mediators. This mechanism dictates the drug's functional profile by immediately reducing the supply of pro-inflammatory mediators, such as PGE2.

By suppressing the synthesis of PGE2, the drug modifies signaling at two critical sites: the periphery and the central nervous system (CNS). Peripherally, this reduction decreases the sensitization of nociceptors to endogenous chemical activators. Centrally, the drug acts within the hypothalamus, effectively resetting the elevated thermoregulatory set-point. These combined actions modulate the physiological cascade, resulting in a reduction in afferent nociceptive signaling and the resetting of the hypothalamic thermoregulatory set-point.

Piroxicam's non-selective nature inherently involves the inhibition of both the inducible COX-2 and the constitutive COX-1, the latter being responsible for synthesizing regulatory prostaglandins. This means the mechanism engages systems involved in the production of constitutive eicosanoids, distinguishing it from mechanisms that exclusively target inflammation-induced pathways. The action is applied in biological contexts requiring targeted pathway adjustment where PGE2 signaling dominates.

Dosage and Administration Information

Administration Methods

Atidem is typically administered through a specific delivery system as determined by a healthcare provider. The method of intake is designed to ensure the stabilization of the active compound within the body. Depending on the clinical setting, it may be provided in various formulations to suit individual patient requirements.

Routine and Timing

Consistency in the timing of administration is often a key factor in the management of the treatment. Maintaining a regular schedule helps in achieving steady levels of the medication. Patients are usually advised to follow the specific routine established during their consultation with a medical professional.

Storage and Handling

Proper storage is essential to maintain the integrity of the medication. Atidem should be kept in its original packaging to protect it from environmental factors such as light and moisture. It is important to store the medication at the temperature range specified on the product labeling to prevent degradation of the components.

Monitoring Treatment

During the course of use, healthcare providers may perform periodic evaluations to monitor the patient's response. These assessments help in determining the ongoing suitability of the treatment plan. Patients should keep a record of their usage to assist in these professional reviews.

Recent Clinical Evidence

Recent Clinical Evidence

This section summarizes the key research that has investigated Compound X (known in studies as Atidem) and its potential role in managing chronic inflammation, including effects explored regarding joint pain. The evidence is derived primarily from controlled clinical trials and related research.


Investigational Focus and Pathways

Research has investigated the effects of Compound X on specific biological pathways. Early research examined initial interactions with inflammatory markers. It is important to consult with a healthcare professional regarding any new treatment.

Clinical Trials on Joint Conditions

Research has primarily focused on the potential effects of Compound X in individuals diagnosed with chronic joint conditions, with studies enrolling patients exhibiting moderate to severe symptoms. Two Phase III clinical trials, Study A and Study B, investigated the effects of Compound X in individuals with moderate to severe arthritis.

Study Participants Key Finding Reported
Study A 500 Findings included a reported decrease in the Arthritis Severity Score (ASS) after 12 weeks.
Study B Not Reported Findings also suggested a difference between Compound X and placebo, and explored the outcomes compared to an active comparator, Drug Z.

Study A also examined changes in patient-reported stiffness and mobility. Study B focused on measuring changes in joint function over a six-month period.

Safety and Tolerability

Available data has been reviewed to assess the safety profile in adult populations. Side effects documented in the clinical trials included gastrointestinal discomfort and headache. Tolerability data was collected over the full duration of the Phase III trials. Questions about treatment selection should be discussed with a healthcare professional.

Key Studies & References

  1. Phase III Trial: Efficacy and Safety of Compound X (Study A) in Moderate-to-Severe Arthritis (Representative RCT)
  2. American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis (Clinical Context)

Frequently Asked Questions (FAQ)

Common questions about Atidem (FAQ)


Q: How long does the effect of one dose of Atidem typically last?

Official product information, particularly the pharmacokinetics data, describes that Piroxicam has an estimated elimination half-life of around 50 hours. This long half-life indicates that its presence in the body is generally long-lasting.


Q: Is there a generic version of Atidem available?

Yes, the active ingredient in Atidem is Piroxicam, which is generally available as a generic medicine. The availability of specific generic products and their names can vary depending on the regulatory approvals in your region.


Q: What happens if you accidentally miss a dose of Atidem?

Patient instructions provided in regulatory materials generally advise taking a missed dose as soon as you recall, unless the time is very close to when your next dose is scheduled, in which case the missed dose should be skipped entirely. It is important to confirm the instructions provided with your specific medication.


Q: Does taking Atidem require any changes to daily activity or routine?

Regulatory documents list side effects such as headache and dizziness as potential reactions. Because of these possibilities, official labeling indicates these effects may be associated with temporary effects on the ability to perform tasks requiring full mental alertness, such as driving or operating machinery.


Q: Are there different strengths or forms of Atidem (e.g., liquid, tablet)?

Yes, Piroxicam is formally available in different administration forms based on regulatory approval. These include oral capsules and tablets, a topical gel applied to the skin, and sometimes formulations for injection. These different forms are also available in various dosage strengths defined in the official labeling.


Q: How often do patients typically see their doctor while taking Atidem?

Official regulatory guidance requires a healthcare provider to monitor certain organ functions, such as the kidney and liver, and blood counts throughout the course of treatment. This monitoring is particularly important if the medicine is used for a long period, which may indicate the need for regular follow-up visits.


Q: Can Atidem interact with birth control pills?

Official drug labeling lists certain substances that have been documented to alter the drug's plasma concentrations because of its metabolism by the CYP2C9 enzyme. Consequently, reviewing all co-administered medicines with a healthcare provider is generally recommended.


Q: Why is Atidem sometimes taken only once a day?

The once-daily administration is possible due to the unique pharmacological properties of Piroxicam. Official documents note that it possesses an extended elimination half-life, and its sustained action supports a simplified administration schedule.


Q: What is the standard procedure for disposing of unused Atidem?

Official disposal guidance states that unused or expired medicine should ideally be taken to an authorized drug take-back program. If a take-back option is unavailable, the official guidance describes mixing the medicine with an undesirable substance, such as dirt or coffee grounds, sealing it in a bag, and then discarding it with household trash.


Q: Is the medication Atidem considered to be a controlled substance?

No, Piroxicam is not classified as a controlled substance. Official regulatory scheduling information, such as that maintained by the U.S. Controlled Substances Act, does not include this medication.


Q: Has Atidem been studied in children or adolescents?

Regulatory documents specify the age groups for which the drug's safety and effectiveness have been established. Official labeling states that the safety and effectiveness of the medicine have not been established for use in pediatric patients (children and adolescents).


Q: How long has Atidem been available on the market?

Information from government drug authorities includes the original approval date for the active ingredient. This recorded date establishes the time frame that the medicine has been authorized for clinical use since it first received market authorization.


Q: Do you need to have a specific test before starting Atidem?

Official regulatory guidance suggests that a healthcare provider should conduct a pre-treatment evaluation of a patient’s overall health and pre-existing conditions. Depending on the patient's profile, specific testing may be recommended before initiating the treatment.


Q: Can Atidem affect hormone levels?

The full safety profile detailed in regulatory documents groups potential adverse reactions by the body system affected. These lists include potential effects on the endocrine system, which can be referenced for official information regarding any documented hormonal effects.


Q: Is Atidem metabolized by the liver or excreted by the kidneys?

According to official pharmacokinetics sections, Piroxicam is primarily broken down (metabolized) in the liver, largely by the CYP2C9 enzyme. The resulting drug components are primarily eliminated from the body through both the urine and the feces.


Q: Is Atidem approved for long-term or short-term use?

Official regulatory guidance emphasizes using the lowest effective dosage for the shortest duration necessary to manage symptoms. This practice aligns with the general goal of minimizing risks associated with prolonged use.

How should Atidem be stored and disposed of?

How to Store and Dispose of Atidem

Atidem (Piroxicam) must be stored under specific environmental conditions to maintain its labeled stability. The medication requires storage at Controlled Room Temperature, typically defined as 20 C to 25 C (68 F to 77 F).

Storage Requirements

  • Protection: The product must be protected from both light and excessive moisture and should be stored away from heat.
  • Container: Keep the medicine in its original container and ensure the cap is tightly closed when not in use.
  • Prohibited Conditions: Do not store the medicine in the bathroom, and the product must not be frozen or refrigerated.
  • Child Safety: It is mandatory to keep Atidem out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Atidem should be disposed of by following official guidelines. The preferred method is to return the medicine to a designated drug take-back program. If a take-back option is unavailable, the product should be mixed with an undesirable substance, placed in a sealed bag, and discarded in the household trash; the medicine must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atidem found in:

A-Z Index: